Forbion Capital Partners

Forbion Capital Partners emerged in 2000 as a spinoff from ABN AMRO Capital Life Sciences, later streamlining its brand to simply "Forbion" to reflect its comprehensive value proposition beyond financial backing. With over two decades of experience in the life sciences sector, this venture capital firm has established itself as a prominent investor dedicated to advancing breakthrough therapies and healthcare innovations. The firm's evolution represents its growing influence and specialized focus within the biotechnology and pharmaceutical investment landscape.

The investment team at Forbion has cultivated an exceptional portfolio through strategic sourcing, development, and guidance of life sciences companies. Their expertise has directly contributed to numerous medical breakthroughs and successful exits that have transformed both patient care and investor returns. Currently managing an impressive €2.3 billion across ten specialized funds, Forbion demonstrates significant financial capacity to support promising ventures at various development stages, from early discovery to commercial growth phases.

As of late 2022, Forbion actively manages 43 portfolio companies while having invested in 95 companies throughout its history. This extensive investment activity is supported by a team of 46 professionals who bring specialized expertise in biotechnology, pharmaceutical development, and healthcare innovation. The firm typically focuses on European and North American companies developing novel therapeutics, medical technologies, and digital health solutions that address significant unmet medical needs. Forbion's investment strategy typically encompasses seed to growth-stage funding, with particular emphasis on companies with disruptive potential.

Forbion has attracted substantial backing from prestigious institutional investors, including the European Investment Fund (EIF) through multiple facilities such as the European Recovery Programme and the Dutch Venture Initiative. Additional key investors include LfA and Kreditanstalt für Wiederaufbau (KFW) through specialized venture capital financing mechanisms. This strong institutional support underscores Forbion's credibility and track record in the competitive life sciences investment sector, while enabling the firm to continue its mission of accelerating medical innovation and delivering both patient impact and financial returns.